These findings substantiate the association between high levels of PD-1/PD-L1 at immune checkpoints and poor prognosis in AML, indicating that targeting the PD-1/PD-L1 signaling pathway may represent a promising therapeutic strategy for this malignancy. The gene discussed is CD274; the disease is acute myeloid leukemia.